AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02739438 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
Study NCT03240848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: artificial intelligent clinic
Description: Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
Study NCT03240848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normal clinic
Description: Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
Study NCT03240848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experts diagnose
Description: After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
Study NCT03240848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: experts diagnose
Description: After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
Study NCT02216058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
Study NCT01683864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: positive cytology with HIPEC
Description: HIPEC with mytomycin and cisplatin
Study NCT00867217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D
Description: High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
Study NCT00867217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00867217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Dose Vitamin D3
Description: Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
Study NCT00867217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Dose Vitamin D3
Description: Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
Study NCT00867217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: All subjects received letrozole as standard of care.
Study NCT00867217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole 2.5mg
Description: All subjects received letrozole as standard of care.
Study NCT01489033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU
Study NCT01489033 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU
Study NCT02415335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone phosphate
Description: Intravenously administration minimum of 30 minutes preoperatively.
Study NCT00989287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340272A
Description: Two intramuscular injections in the deltoid region of the non-dominant arm.
Study NCT00989287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340269A
Description: Two intramuscular injections in the deltoid region of the non-dominant arm.
Study NCT01995461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilateral transforaminal epidural steroid injections
Description: BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
Study NCT04298138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
Study NCT02415335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Intravenously administration minimum of 30 minutes preoperatively
Study NCT05610865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control; Standard-of-care management
Description: Patients will undergo conventional wound care management.
Study NCT05610865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Only PRP injection
Description: Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
Study NCT05610865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP + SVF injection
Description: Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
Study NCT05610865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP + ASCs injection
Description: Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
Study NCT03240692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated theta-burst stimulation treatment
Description: All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system.
Study NCT02640807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) >2.5 or platelet count \< 35,000
Study NCT02640807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count \< 35,000
Study NCT02640807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count \< 35,000
Study NCT00515112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel
Description: Androgel 1%, 10g daily
Study NCT00515112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01825785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT01825785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT02910336 — intervention group
Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: sensory testing profile
Study NCT03759132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
Study NCT03303690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle Spacer (AS)
Description: All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
Study NCT04203602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telepresence discharge
Description: Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
Study NCT04203602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional discharge
Description: Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
Study NCT02291666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRCHUM-MT cocktail
Study NCT02291666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRCHUM-MT cocktail
Study NCT00894608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole + gonadotropins
Description: patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
Study NCT00894608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa + gonadotropins
Description: patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
Study NCT02483221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
Study NCT02483221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
Study NCT01308021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
Study NCT01308021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
Study NCT01308021 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo entero-coated capsules
Study NCT03545685 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: specific memory and attention realtime training
Description: The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
Study NCT01857531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three.
Study NCT01857531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week).
Study NCT04304144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
Study NCT04304144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)
Description: According to institutional standard of care.
Study NCT04304144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Treatment for AL amyloidosis
Study NCT00827450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ctl
Description: Control, isocaloric diet; no coffee
Study NCT00827450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High fructose diet; no coffee
Description: Hypercaloric, high fructose diet; no coffee
Study NCT00827450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fully torrefied, caffeine-free coffee
Description: Hypercaloric, high fructose diet + coffee
Study NCT00827450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: partially torrefied, caffeine-free coffee
Description: Hypercaloric, high fructose diet + coffee
Study NCT00827450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially torrefied, caffeinated coffee
Description: Hypercaloric, high fructose diet + coffee
Study NCT04271956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
Study NCT04271956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
Study NCT04271956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po
Study NCT03759132 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
Study NCT03545685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific memory and attention realtime training
Description: The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
Study NCT02313168 — intervention group
Intervention type: OTHER
Intervention: observation, inspection
Study NCT04091789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pure Femme Tablets
Description: A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
Study NCT03324620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific program functional and respiratory rehabilitation
Description: It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
Study NCT04957251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior approach to the hip
Description: anterior hip hemiarthroplasty
Study NCT04957251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior approach to the hip
Description: posterior hip hemiarthroplasty
Study NCT00464958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual tizanidine 12 mg
Description: Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
Study NCT02737254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children >40kg administer 24IU.
Study NCT02737254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children >40kg administer 24IU.
Study NCT02737254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9 % nasal spray.
Study NCT02737254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9 % nasal spray.
Study NCT02737254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secure CBM training
Description: Children are trained to interpret ambiguous maternal behavior in a secure way.
Study NCT02737254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secure CBM training
Description: Children are trained to interpret ambiguous maternal behavior in a secure way.
Study NCT02737254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral CBM training
Description: Children receive a training unrelated to the interpretation of maternal behavior.
Study NCT02737254 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral CBM training
Description: Children receive a training unrelated to the interpretation of maternal behavior.
Study NCT04573049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
Study NCT04573049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
Study NCT03316651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months.
Study NCT00780130 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: male \& female college students ages 20 to 50, asymptomatic normals
Study NCT03033368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg tablet
Study NCT00838656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV in one of two schedules
Study NCT00838656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV in one of two schedules
Study NCT00838656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV in one of two schedules
Study NCT03719781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: standardized minimental testing
Description: To diagnose postoperative cognitive dysfunction
Study NCT03252977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored regimen of IV PCA according to pain sensitivity
Description: In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
Study NCT03252977 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Regimen of IV PCA without considering pain sensitivity
Description: In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
Study NCT01962012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent Aura
Study NCT01962012 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Study NCT00424619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: 50 000 IU vitamin D2, one time bolus dose